New Approaches in Early-Stage NSCL Management: Potential Use of PARP Inhibitors and Immunotherapy Combination

Lung cancer is the second most common cancer in the world, being the first cause of cancer-related mortality. Surgery remains the only potentially curative treatment for Non-Small Cell Lung Cancer (NSCLC), but the recurrence risk remains high (30–55%) and Overall Survival (OS) is still lower than de...

Descripción completa

Detalles Bibliográficos
Autores principales: Fernandes, Marta Pina, Oliveira, Cristina, Sousa, Hugo, Oliveira, Júlio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9961654/
https://www.ncbi.nlm.nih.gov/pubmed/36835456
http://dx.doi.org/10.3390/ijms24044044

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9961654/
https://www.ncbi.nlm.nih.gov/pubmed/36835456
http://dx.doi.org/10.3390/ijms24044044

Ejemplares similares